<div id="readability-page-1"><p>PharVision Advisers LLC purchased a new stake in shares of  Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 18,644 shares of the company's stock, valued at approximately $245,000.</p><ul><li>Medtronic: A Dividend Aristocrat With Stability and Innovation</li></ul><p>A number of other large investors have also made changes to their positions in the company. Nomura Asset Management Co. Ltd. increased its stake in  Pediatrix Medical Group by 95.3% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 2,500 shares of the company's stock valued at $33,000 after buying an additional 1,220 shares during the period.  Parkside Financial Bank &amp; Trust boosted its holdings in shares of  Pediatrix Medical Group by 36.1% during the 4th quarter. Parkside Financial Bank &amp; Trust now owns 3,919 shares of the company's stock worth $51,000 after buying an additional 1,040 shares during the period.  AlphaQuest LLC boosted its holdings in shares of  Pediatrix Medical Group by 65.9% during the 4th quarter. AlphaQuest LLC now owns 5,066 shares of the company's stock worth $66,000 after buying an additional 2,012 shares during the period.  Smartleaf Asset Management LLC boosted its holdings in  Pediatrix Medical Group by 750.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 6,901 shares of the company's stock valued at $91,000 after purchasing an additional 6,090 shares during the period.  Finally, Tower Research Capital LLC TRC boosted its holdings in  Pediatrix Medical Group by 218.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,445 shares of the company's stock valued at $98,000 after purchasing an additional 5,104 shares during the period. Institutional investors and hedge funds own  97.71% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>A number of equities research analysts recently issued reports on MD shares. UBS Group dropped their target price on shares of Pediatrix Medical Group from $18.50 to $16.00 and set a &#34;neutral&#34; rating for the company in a research report on Monday, May 12th. Truist Financial lowered their price objective on shares of Pediatrix Medical Group from $18.00 to $16.00 and set a &#34;hold&#34; rating for the company in a research report on Friday, April 11th. Finally, Macquarie raised their price objective on shares of Pediatrix Medical Group from $19.00 to $20.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $16.67.</p><ul><li>MarketBeat Week in Review – 02/17 - 02/21</li></ul><p><b>Get Our Latest Stock Analysis on MD</b></p><h2>Pediatrix Medical Group Stock Down 7.9%</h2><p>Shares of NYSE MD opened at $13.98 on Friday. The firm has a market capitalization of $1.20 billion, a PE ratio of -11.65, a price-to-earnings-growth ratio of 1.74 and a beta of 1.26. The company has a current ratio of 1.60, a quick ratio of 1.42 and a debt-to-equity ratio of 0.81. Pediatrix Medical Group, Inc. has a 1 year low of $6.62 and a 1 year high of $17.67. The firm's 50-day moving average is $13.78 and its 200-day moving average is $14.12. </p><ul><li>Medtronic’s Expansion Gains Momentum—Time for a Market Shift?</li></ul><p>Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.08. The company had revenue of $458.36 million for the quarter, compared to analyst estimates of $451.44 million. Pediatrix Medical Group had a negative net margin of 4.92% and a positive return on equity of 15.47%. The company's revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.20 EPS.  Equities analysts expect that  Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year. </p><h2>About Pediatrix Medical Group</h2> (Free Report)<p>Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Pediatrix Medical Group</li><li>What is the Australian Securities Exchange (ASX) </li><li>Turbulence for Joby Shares: What's Behind the Recent Dip?</li><li>3 Small Caps With Big Return Potential</li><li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li><li>3 Best Fintech Stocks for a Portfolio Boost</li><li>Super Micro Computer Stock Clears New Path Higher on Saudi Orders</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1E?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1E"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pediatrix Medical Group Right Now?</h2><p>Before you consider Pediatrix Medical Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.</p><p>While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>PharVision Advisers LLC has acquired a new stake in Pediatrix Medical Group, Inc. (NYSE:MD), purchasing 18,644 shares valued at approximately $245,000 during the fourth quarter. Other institutional investors have also increased their positions in the company. Analysts have set a consensus rating of "Hold" for the stock, with an average price target of $16.67. Pediatrix Medical Group reported earnings of $0.33 per share for the last quarter, exceeding estimates, but its revenue declined by 7.4% year-over-year.</p>

PharVision Advisers LLC Takes $245,000 Position in Pediatrix Medical Group, Inc. (NYSE:MD)